U.S. Markets close in 4 hrs 41 mins

Canadian National Railway and Three Additional Services Stocks on Investors’ Radar

Stock Research Monitor: WAB, MYGN, and QGEN

LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want a free Stock Review on CNI sign up now at www.wallstequities.com/registration. On Tuesday, May 15, 2018, US markets saw broad based losses with all sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 7,351.63, down 0.81%; the Dow Jones Industrial Average edged 0.78% lower, to finish at 24,706.41; and the S&P 500 closed at 2,711.45, down 0.68%. This Wednesday morning, WallStEquities.com looks at the performance of these four Services stocks: Canadian National Railway Co. (NYSE: CNI), Westinghouse Air Brake Technologies Corp. (NYSE: WAB), Myriad Genetics Inc. (NASDAQ: MYGN), and QIAGEN N.V. (NYSE: QGEN). All you have to do is sign up today for this free limited time offer by clicking the link below.


Canadian National Railway

On Tuesday, shares in Montreal, Canada headquartered Canadian National Railway Co. recorded a trading volume of 1.62 million shares, which was above their three months average volume of 1.50 million shares. The stock ended the session 1.38% higher at $80.74. The Company's shares have gained 7.15% in the last month. The stock is trading above its 50-day and 200-day moving averages by 7.51% and 2.34%, respectively. Moreover, shares of the Company, which engages in rail and related transportation business, have a Relative Strength Index (RSI) of 68.95.

On May 14th, 2018, research firm Goldman downgraded the Company's stock rating from 'Buy' to 'Neutral'. Get the full research report on CNI for free by clicking below at:


Westinghouse Air Brake Technologies

Wilmerding, Pennsylvania headquartered Westinghouse Air Brake Technologies Corp.'s stock closed the day 0.01% higher at $93.19 with a total trading volume of 549,052 shares. The Company's shares have advanced 12.02% in the past month, 29.47% in the previous three months, and 16.01% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 10.17% and 18.91%, respectively. Additionally, shares of the Company, which provides technology-based equipment, systems, and services for the freight rail and passenger transit vehicle industries worldwide, have an RSI of 69.48.

On April 23rd, 2018, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $75 a share to $99 a share. Free research on WAB can be accessed at:


Myriad Genetics

Shares in Salt Lake City, Utah headquartered Myriad Genetics Inc. recorded a trading volume of 603,891 shares. The stock ended yesterday's trading session 1.94% lower at $33.81. The Company's shares have advanced 16.99% in the past month and 51.89% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 12.96% and 4.72%, respectively. Furthermore, shares of Myriad Genetics, which focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide, have an RSI of 67.40. Sign up today for the free research report on MYGN at:



Venlo, the Netherlands headquartered QIAGEN N.V.'s stock finished Tuesday's session 1.41% lower at $34.98 with a total trading volume of 429,592 shares. The Company's shares have advanced 9.28% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 5.44% and 7.17%, respectively. Additionally, shares of QIAGEN, which provides sample to insight solutions that transform biological materials into molecular insights worldwide, have an RSI of 62.77. Wall St. Equities' research coverage also includes the downloadable free report on QGEN at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities